DXCM DEXCOM INC.

Dexcom, Adam Schefter Announce Dexcom U, the First NIL Program for College Athletes With Diabetes

(NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of , the first-ever NIL (name, image, likeness) program designed to celebrate college athletes with diabetes and inspire people with diabetes who have athletic dreams of their own.

This press release features multimedia. View the full release here:

Dexcom U is designed to celebrate college athletes with diabetes and inspire people with diabetes who have athletic dreams of their own. (Graphic: Business Wire)

Dexcom U is designed to celebrate college athletes with diabetes and inspire people with diabetes who have athletic dreams of their own. (Graphic: Business Wire)

A recent survey shows the toll of diabetes can potentially halt budding athletic talent and prevent newly diagnosed people from pursuing their dreams. The survey found that nearly half (43%) of adults with Type 1 diabetes felt like quitting sports and physical activities because of their diagnosis, and one in five (20%) followed through with quitting sports.1

The program, led by Dexcom in partnership with ESPN Senior NFL Insider and diabetes advocate Adam Schefter, whose wife Sharri lives with Type 1 diabetes, will offer 14 competitors a platform to share their story, act as role models to other aspiring athletes and receive mentorship and support from their Dexcom U teammates, professional athletes and figures who understand the challenges facing athletes with diabetes.

“For many, having diabetes used to mean giving up on your hopes and dreams,” said Adam Schefter. “I’ve had a front-row seat to diabetes since my wife Sharri was diagnosed in 2002, and I see the hurdles that people with diabetes overcome daily, but also how the advances in diabetes care, like Dexcom CGM, have unlocked a world of possibilities for her and many others.”

The following athletes make up Dexcom U’s inaugural roster:

  • Ali Watson, Diving, Duke University
  • Ava DeStefon, Cheerleading, Clemson University
  • Bri Carrasquillo, Lacrosse, Yale University
  • Bryce Frederick, Baseball, Towson University
  • Cade Brown, Baseball, University of Oklahoma
  • Caleb Fauria, Football, University of Colorado
  • Carly Graham, Volleyball, Rice University
  • Grant Waszak, Swimming, University of Nebraska Omaha
  • Isaac Traudt, Basketball, University of Virginia
  • Jarod Verkleeren, Wrestling, University of Virginia
  • Leo Giannoni, Baseball, Columbus State University
  • Marlee Fray, Soccer, University of Texas at San Antonio
  • Paris Husic, Track & Field, Wake Forest University
  • Zyian Welcher, Cheerleading, Jackson State University

In addition to the support they receive from coaches, teammates and loved ones, these athletes rely on their Dexcom continuous glucose monitoring (CGM) systems to track their glucose levels* in real-time without the need for painful fingerpicks, empowering them to better manage their diabetes while breaking new barriers in their respective sports.

“Dexcom has always celebrated people with diabetes who push the limits and make a positive impact on their communities, which is why we saw the Supreme Court’s NIL decision as an opportunity to elevate these outstanding young athletes,” said Anne Santoro, VP global customer experience at Dexcom. “The creation of Dexcom U is a testament to how our Warriors are breaking barriers and leading the way as role models for others with diabetes.”

Additional key findings from the survey include:

  • A diabetes diagnosis can be harrowing and lonesome:
    • Two-thirds (66%) of adults with Type 1 diabetes surveyed felt alone because of the disease shortly after diagnosis and almost half (48%) felt the need to hide their diabetes from others during this time.1
    • 50% of adults with Type 1 diabetes felt that their coaches, trainers and teachers treated them differently after learning about their diagnosis.1
  • Modern diabetes technology is empowering people with diabetes to pursue their goals:
    • 82% of CGM users say the technology is very beneficial in helping them achieve their aspirations.1
  • Representation for people with diabetes can help inspire the next generation of college and professional athletes:
    • Nearly half (48%) of adults with Type 1 diabetes and parents to children with diabetes believe that being aware of a professional or top, amateur athlete or celebrity with Type 1 diabetes would be very beneficial for a newly diagnosed individual.1

“My Dexcom CGM is a total game-changer, allowing me to compete at the highest level knowing my diabetes is under control, and giving me, my coaches and teammates peace of mind,” said Zyian Welcher, cheerleader at Jackson State University. “I know first-hand that having role models who know exactly what it’s like to live with diabetes can be a tremendous asset, so it’s a great privilege to be part of Dexcom U and hopefully be that role model for someone else.”

In addition to welcoming new athletes each year, Dexcom will share free educational resources designed for parents, teachers, coaches and fellow athletes to break down misconceptions about diabetes and reinforce that diabetes doesn’t need to get in the way of achieving one’s athletic dreams and aspirations.

Dexcom will host a Facebook streaming event on October 24 at 9:00 a.m. PST to celebrate the Dexcom U launch. To learn more about Dexcom U and access the free educational resources, please visit .

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit .

* For a list of compatible devices, visit .

† If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

1 Dexcom, U.S. data on file, September 2022

EN
24/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DEXCOM INC.

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Dexcom Inc: 2 directors

Two Directors at Dexcom Inc sold 16,184 shares at between 84.285USD and 85.110USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

OSK OSHKOSH CORP
DXCM DEXCOM INC.
XRAY DENTSPLY SIRONA INC.
WING WINGSTOP INC.
VRTS VIRTUS INVESTMENT PARTNERS INC.
UHS UNIVERSAL HEALTH SERVICES INC. CLASS B
STKS ONE GROUP HOSPITALITY
SNPS SYNOPSYS INC.
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
SFST SOUTHERN FIRST BANCSHARES
RGNX REGENXBIO INC.
RCKY ROCKY BRANDS
PRGO PERRIGO CO. PLC
MPWR MONOLITHIC POWER SYSTEMS INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
IRM IRON MOUNTAIN INC.
GPC GENUINE PARTS COMPANY
GD GENERAL DYNAMICS CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CROX CROCS INC.
CAL CALERES INC.
BKE BUCKLE INC.
ASC ARDMORE SHIPPING
AMOT ALLIED MOTION TECHNOLOGIES
ACAD ACADIA PHARMACEUTICALS INC.
SBL SAFE BULKERS INC.
LPG DORIAN LPG
MEG. MEG ENERGY CORP.
MDU MDU RESOURCES GROUP INC
NAT NORDIC AMERICAN TANKERS LIMITED
EVTC EVERTEC INC.
FSLR FIRST SOLAR INC.
IONS IONIS PHARMACEUTICALS INC.
NMIH NMI HOLDINGS INC. CLASS A
AGYS AGILYSYS INC.
SJM J.M. SMUCKER COMPANY
FIZZ NATIONAL BEVERAGE CORP.
NHC NATIONAL HEALTHCARE CORP.
INSW INTERNATIONAL SEAWAYS INC.
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
CELH CELSIUS HOLDINGS INC.
AMD ADVANCED MICRO DEVICES INC.
TTEC TTEC HOLDINGS INC.
AVGO BROADCOM INC.
ST SENSATA TECHNOLOGIES HOLDING PLC
ELAN ELANCO ANIMAL HEALTH INC.
MEC MAYVILLE ENGINEERING
DELL DELL TECHNOLOGIES INC CLASS C
CSTM CONSTELLIUM SE CLASS A
OI O-I GLASS INC
BWMN BOWMAN CONSULTING GROUP LTD
DINO HOLLYFRONTIER CORP
EVEX EVE HOLDING INC
SPXC SPX TECHNOLOGIES INC
WEST WESTROCK COFFEE COMPANY LLC
ADCT ADC THERAPEUTICS SA
SVV SAVERS VALUE VILLAGE INC
GUTS FRACTYL HEALTH INC
AGEN AGENUS INC.
ARDT ARDENT HEALTH PARTNERS INC
PCT PROVIDENT CAP TR II SKIS 8.75%29
MKTW MARKETWISE INC
 PRESS RELEASE

Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medi...

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable insights into access to care and perceptions of diabetes technology. During the conference, first-ever accuracy a...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch